Aric C. Hall

3.0k total citations
25 papers, 412 citations indexed

About

Aric C. Hall is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Aric C. Hall has authored 25 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 7 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Aric C. Hall's work include Multiple Myeloma Research and Treatments (10 papers), Acute Myeloid Leukemia Research (9 papers) and Protein Degradation and Inhibitors (5 papers). Aric C. Hall is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Acute Myeloid Leukemia Research (9 papers) and Protein Degradation and Inhibitors (5 papers). Aric C. Hall collaborates with scholars based in United States. Aric C. Hall's co-authors include Mark Juckett, Natalie S. Callander, Robert F. Cornell, Parameswaran Hari, Rebecca Silbermann, Pamela Hardwick, Kelly Godby, Luciano J. Costa, Eva Medvedova and Saurabh Chhabra and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nutrients.

In The Last Decade

Aric C. Hall

21 papers receiving 404 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aric C. Hall United States 8 335 262 202 40 32 25 412
Thomas G Martin United States 10 369 1.1× 318 1.2× 263 1.3× 36 0.9× 25 0.8× 19 504
Vladimír Maisnar Czechia 13 393 1.2× 323 1.2× 238 1.2× 92 2.3× 29 0.9× 80 467
Serena Rocchi Italy 9 255 0.8× 180 0.7× 157 0.8× 33 0.8× 26 0.8× 31 301
David Siegel United States 9 390 1.2× 341 1.3× 265 1.3× 43 1.1× 22 0.7× 23 529
Xenofon Papanikolaou United States 7 241 0.7× 167 0.6× 150 0.7× 50 1.3× 20 0.6× 30 310
Sunhee Ro United States 8 213 0.6× 229 0.9× 178 0.9× 54 1.4× 38 1.2× 19 380
Marcelo Capra Brazil 11 211 0.6× 129 0.5× 202 1.0× 48 1.2× 39 1.2× 40 336
Nuriet K. Khuageva Russia 8 563 1.7× 445 1.7× 384 1.9× 75 1.9× 31 1.0× 13 629
Alessandra Bertola Italy 10 520 1.6× 369 1.4× 330 1.6× 63 1.6× 15 0.5× 13 569
Peter A. Forsberg United States 10 199 0.6× 137 0.5× 165 0.8× 30 0.8× 10 0.3× 40 359

Countries citing papers authored by Aric C. Hall

Since Specialization
Citations

This map shows the geographic impact of Aric C. Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aric C. Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aric C. Hall more than expected).

Fields of papers citing papers by Aric C. Hall

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aric C. Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aric C. Hall. The network helps show where Aric C. Hall may publish in the future.

Co-authorship network of co-authors of Aric C. Hall

This figure shows the co-authorship network connecting the top 25 collaborators of Aric C. Hall. A scholar is included among the top collaborators of Aric C. Hall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aric C. Hall. Aric C. Hall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brunner, Matthew, Michael J. Fallon, Ryan J. Mattison, et al.. (2024). Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia. JCO Precision Oncology. 8(8). e2300518–e2300518. 1 indexed citations
2.
Bräuer, Markus, et al.. (2024). Balancing risks and rewards: How hematologists discuss uncertainty in allogeneic hematopoietic cell transplantation outcomes. Patient Education and Counseling. 123. 108177–108177. 2 indexed citations
3.
Bräuer, Markus, et al.. (2024). Communication Strategies of Transplant Hematologists in High-Risk Decision-Making Conversations. JCO Oncology Practice. 20(4). 538–548. 2 indexed citations
4.
Hall, Aric C., et al.. (2024). “Things we deal with in exchange for cure”: How hematologists discuss graft versus host disease with patients considering allogeneic stem cell transplant.. Journal of Clinical Oncology. 42(16_suppl). 12109–12109. 1 indexed citations
5.
Bräuer, Markus, et al.. (2023). “Transplant Changes Your Life”: Communication Strategies of Transplant Hematologists in High Risk Decision Making Conversations. Blood. 142(Supplement 1). 2349–2349. 1 indexed citations
6.
Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2023). Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. The Lancet Haematology. 10(11). e890–e901. 71 indexed citations
7.
Kenkre, Vaishalee P., Matthew Brunner, Zhubin Gahvari, et al.. (2023). Full Body Screening Computed Tomography Prior to Allogeneic Hematopoietic Stem Cell Transplantation: A Single Institution Experience from an Academic Center. Blood. 142(Supplement 1). 378–378.
8.
Bashir, Qaiser, Taiga Nishihori, Marcelo C. Pasquini, et al.. (2022). A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. Transplantation and Cellular Therapy. 29(6). 358.e1–358.e7. 5 indexed citations
9.
10.
11.
Bal, Susan, Binod Dhakal, Rebecca Silbermann, et al.. (2022). Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy. American Journal of Hematology. 97(9). 1170–1177. 5 indexed citations
12.
Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2021). Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology. 40(25). 2901–2912. 146 indexed citations
13.
14.
Bal, Susan, Saurabh Chhabra, Natalie S. Callander, et al.. (2021). Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy. Blood. 138(Supplement 1). 483–483. 2 indexed citations
15.
16.
Mushtaq, Muhammad Umair, Alexandra M. Harrington, Sibgha Gull Chaudhary, et al.. (2020). Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. Leukemia & lymphoma. 62(1). 158–166. 15 indexed citations
17.
Dhakal, Binod, Raphael Fraser, Zhubin Gahvari, et al.. (2019). Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM). Blood. 134(Supplement_1). 783–783. 1 indexed citations
18.
19.
Hutson, Paul R., Zachary Williams, Natalie S. Callander, et al.. (2018). Outcomes of BeEAM (bendamustine, etoposide, cytarabine, melphalan) Compared to BEAM (carmustine, etoposide, cytarabine, melphalan) for High Dose Chemotherapy Followed By Autologous Stem Cell Transplant. Biology of Blood and Marrow Transplantation. 24(3). S134–S134. 1 indexed citations
20.
Mushtaq, Muhammad Umair, Sibgha Gull Chaudhary, Guru Subramanian Guru Murthy, et al.. (2018). Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Relapsed/Refractory Acute Myeloid Leukemia. Blood. 132(Supplement 1). 5246–5246. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas G Martin Breakdown of academic impact, for papers by Vladimír Maisnar Breakdown of academic impact, for papers by Serena Rocchi Breakdown of academic impact, for papers by David Siegel Breakdown of academic impact, for papers by Xenofon Papanikolaou Breakdown of academic impact, for papers by Sunhee Ro Breakdown of academic impact, for papers by Marcelo Capra Breakdown of academic impact, for papers by Nuriet K. Khuageva Breakdown of academic impact, for papers by Alessandra Bertola Breakdown of academic impact, for papers by Peter A. Forsberg
Rankless by CCL
2026